Oncology Data Advisor™ · Investigating Momelotinib for Treatment of Myelofibrosis With Srdan Verstovsek, MD, PhD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Srdan Verstovsek, Chief of the Section for Myeloproliferative Neoplasms in the Department of Leukemia at MD Anderson Cancer Center, sat down to discuss his presentation on the results of research regarding momelotinib in treatment of myelofibrosis. This podcast episode was recorded live by Oncology Dat...
At the recent American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Irving Weissman, Director of the Institute of Stem Cell Biology and Regenerative Medicine at Stanford University, received the 2022 Wallace H. Coulter Award for Lifetime Achievement in Hematology. In this interview, Dr. Weissman tells the story of how he entered the field, describes the monumental contributions he has made in hematology and oncology, and shares advice for medical students who are interested in becoming involved in basic science research.
At the recent American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Irving Weissman, Director of the Institute of Stem Cell Biology and Regenerative Medicine at Stanford University, received the 2022 Wallace H. Coulter Award for Lifetime Achievement in Hematology. In this interview, Dr. Weissman tells the story of how he entered the field, describes the monumental contributions he has made in hematology and oncology, and shares advice for medical students who are interested in becoming involved in basic science research.
Oncology Data Advisor™ · Exploring the Results of Elranatamab for Relapsed/Refractory Multiple Myeloma With Noopur Raje, MD Recently, Dr. Noopur Raje, Director of the Center for Multiple Myeloma at Massachusetts General Hospital, sat down with Oncology Data Advisor at the 64th American Society of Hematology (ASH) Annual Meeting to discuss the results of the MagnetisMM-1 study of elranatamab for multiple myeloma that she presented. Dr. Raje elaborates on the efficacy and safety of th...
The FDA has granted approval to crizotinib (Xalkori®, Pfizer) for treatment of unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase (ALK)–positive inflammatory myofibroblastic tumors (IMTs) in adult or pediatric patients one year and older. "ALK is a receptor tyrosine kinase (RTK) that is known to be oncogenically activated by point mutations within the tyrosine kinase domain, copy-number amplification, or chromosomal translocations" wrote Jennifer Foster, MD, MPH, Dire...
Immune thrombocytopenia (ITP) is a heterogeneous disorder that involves a shortage of platelets, or thrombocytes, and can result in excessive bruising or bleeding. Diagnosis and treatment are challenging due to the lack of specific diagnostic criteria and the widely varying clinical features: some patients remain asymptomatic, whereas others experience troublesome bruising or even life-threatening intracranial hemorrhage. The optimal management of ITP necessitates an individualized approach that...
In order to identify the continuing medical education needs and preferences of hematology/oncology fellows, i3 Health administered a survey to participants at several live CME-certified visiting faculty meetings. i3 Health intends to use the results gathered from the survey in the planning and implementation of CME-certified activities. Of the 54 participants who completed surveys, 80% felt that they had adequate time for self-education activities during their fellowship program, compared with 2...
Recently, the FDA approved glasdegib (DaurismoÔ, Pfizer Labs) to be used in combination with low-dose cytarabine (LDAC) for newly diagnosed acute myeloid leukemia (AML) in elderly patients or those ineligible to receive intensive induction chemotherapy. Richard Pazdur, MD, Director of the FDA's Oncology Center of Excellence and Acting Director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research, explained, "Intensive chemotherapy is usually used...